Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains


The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induces antibody-dependent cellular cytotoxicity (ADCC) indicating its potential use for therapeutic vaccine strategies. Further, 10E8 is a tool for immunogen design and validation of immunogen structure.

NIAID is currently developing certain embodiments of 10E8 for clinical use. Therefore, for some fields of use, NIH will evaluate a license applicant's capabilities and experience in advancing similar technologies through the regulatory process. This technology is not eligible for the NIH's start-up license program.

Potential Commercial Applications: Competitive Advantages:
  • Passive protection to prevent HIV infection
  • Passive protection to prevent mother-to-infant HIV transmission
  • Topical microbicide to prevent HIV infection
  • Gene-based vectors for anti-gp41 antibody expression
  • Therapeutic for the elimination of HIV infected cells that are actively producing virus
 
  • One of the most potent Human broadly-neutralizing anti HIV antibodies isolated to date
  • Broad reactivity and high affinity to most HIV-1 strains
  • Activity is highly complementary to existing broadly neutralizing antibodies, such as CD4 binding site antibodies
  • Not auto-reactive


Related Invention(s):



Inventors:
John Mascola (NIAID)
Mark Connors (NIAID)
Leo Laub (NIAID)
Jinghe Huang (NIAID)
Peter Kwong (NIAID)
Gilad Ofek (NIAID)
Jiang Zhu (NIAID)
Gary Nabel (NIAID)
Rebecca Rudicell (NIAID)
Ivelin Georgiev (NIAID)
Yougping Yang (NIAID)
Baoshan Zhang (NIAID)


Intellectual Property:
US Application No. 61/556,660
US Application No. 61/672,708
US Application No. 61/698,480
PCT Application No. PCT/US2012/063958
US Application No. 14/356,557


Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize 10E8-related vaccines or immunotherapies. For collaboration opportunities, please contact Bill Ronnenberg at +1 240-627-3726 or wronnenberg@niaid.nih.gov.


Licensing Contact:
Cristina Thalhammer-Reyero , Ph.D., M.B.A.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325 Room 33
Rockville , MD 20852
Email: thalhamc@mail.nih.gov
Phone: 301-435-4507
Fax: 301-402-0220

OTT Reference No: E-253-2011/0

Updated: 06/18/2014